Patents Assigned to NAL PHARMACEUTICAL GROUP LIMITED
  • Publication number: 20210244651
    Abstract: An anti-wrinkle cosmetic composition comprises a Kava extract, one or more penetration and other anti-wrinkle agents. The Kava extract is extracted from Piper Methysticum root, leaf, stem, or their combinations.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 12, 2021
    Applicant: NAL PHARMACEUTICAL GROUP LIMITED
    Inventor: Chun Kwong CHU
  • Publication number: 20200230068
    Abstract: Nanoparticles and microspheres are provided for delivering an anticancer agent or other active agents to a subject. The nanoparticles and the microspheres are formed from a core that is encased by a coating or shell that includes a somatostatin-albumin fusion protein or analogue thereof. The somatostatin-albumin fusion protein includes at least one albumin (or an analog thereof) moiety, at least one somatostatin moiety (e.g. SST-14, SST-28), and at least one spacer connecting albumin to albumin, somatostatin to somatostatin and/or albumin to somatostatin moieties.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 23, 2020
    Applicant: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Y. Joseph MO, Xudong YUAN
  • Patent number: 10682370
    Abstract: The present invention provides a novel pharmaceutical composition and method of making the same. The composition comprises an effective amount of an antiviral agent and a local anesthetic. The antiviral drug can be sorivudine. The local anesthetic can be lidocaine or its pharmaceutically acceptable salt. Herpes virus infections in humans can be caused by different human herpes viruses, the most common being herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 16, 2020
    Assignee: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Je Phil Ryoo, Chun Kwong Chu
  • Publication number: 20200155766
    Abstract: The present invention relates to a pre-filled syringe containing Moxifloxacin has a plunger, a barrel, a needle with gauge, kits having this syringe and the use of the syringe for the administration of Moxifloxacin for postsurgical bacterial endophthalmitis after cataract surgery.
    Type: Application
    Filed: April 11, 2018
    Publication date: May 21, 2020
    Applicant: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Y. Joseph MO, Xudong YUAN
  • Patent number: 10195408
    Abstract: Certain embodiments of the invention relates to a transdermal drug delivery system containing donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, more specifically to a transdermal drug delivery system containing a drug-containing matrix layer comprising donepezil or its pharmaceutically acceptable salt, a styrene copolymer, a hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 5, 2019
    Assignee: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Y. Joseph Mo, Tiffany Kawai
  • Patent number: 9693970
    Abstract: The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 4, 2017
    Assignee: NAL PHARMACEUTICALS GROUP LIMITED
    Inventor: Y. Joseph Mo
  • Patent number: 9579295
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: February 28, 2017
    Assignee: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Publication number: 20170002057
    Abstract: The invention is related to fusion proteins of human somatostatin (e.g., SST-14 or SST-28) and human serum albumin, comprising a region at least 85% homologous to human somatostatin and a region at least 85% homologous to human serum albumin or a region with a partial amino acid sequence of human serum albumin, wherein linker peptide sequences may be present between somatostatin and somatostatin moieties or somatostatin and albumin moieties. Also disclosed are constructs wherein the somatostatin moiety contains multiple tandem repeats of a somatostatin sequence. In selected embodiments, the orientation of the somatostatin and albumin moieties can be varied, and such sequences may impact the binding and efficacy of the disclosed fusion proteins. Also disclosed are methods of making and using the aforementioned constructs. The somatostatin-albumin fusion protein demonstrated enhanced stability when incubated in rat plasma in vitro and prolonged plasma half-life in vivo compared with free somatostatin.
    Type: Application
    Filed: August 26, 2016
    Publication date: January 5, 2017
    Applicant: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Y. Joseph MO, Chun Kwong CHU